A phase II clinical trial of poziotinib for non-small cell lung cancer with epidermal growth factor receptor exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer Center, found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may impact future clinical trials for EGFR exon 20 targeted therapies.
Giulio Draetta was recently named chief strategy officer at Orionis Biosciences, a privately held, clinical stage life sciences company focused on discovery, design, and development of precision medicines for cancer and immune system-related disorders. Orionis is based in Boston and Ghent, Belgium.
